Inhibikase Therapeutics, Inc.IKTNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank63
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Latest
-5.79%
↑ 96% vs avg
Percentile
P63
Within normal range
Streak
1 yr
Consecutive declineDecelerating
Average
-137.84%
Historical baseline
PeriodValue
2024-5.79%
2023-2.87%
2022-23.06%
2021-1165.95%
2020-233.84%
2019-147.31%
2018665.69%
2017-327.39%
20160.00%